SCHEMBL3730076

SCHEMBL3730076

CC(C)(C)OC(=O)N1CC(Sc2ccccc2)CC1=O

nearest known ligand 0.46

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
GPR119 Q8TDV5 1/20 0.40
KDM1A O60341 1/20 0.39
RORC P51449 3/20 0.39
KLK7 P49862 1/20 0.37
HDAC1 Q13547 1/20 0.37
HDAC6 Q9UBN7 1/20 0.37
KDM4E B2RXH2 1/20 0.37
PKM P14618 1/20 0.37
NAMPT P43490 1/20 0.37
USP30 Q70CQ3 2/20 0.37
BCHE P06276 1/20 0.37
ALDH1A1 P00352 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15212446 0.80 RORC (0.50) GPR119RORCKDM4EPKMNAMPT
SCHEMBL3128872 0.78 GPR119 (0.61) MEN1KMT2AGPR119KDM4EPKM
SCHEMBL3741353 0.78 MEN1 (0.74) MEN1KMT2ARORCPKMALDH1A1
SCHEMBL3733942 0.76 USP30 (0.53) MEN1KMT2AGPR119KDM1ARORC
SCHEMBL21562814 0.75 RORC (0.39) GPR119KDM1ARORCKDM4EPKM
SCHEMBL13172926 0.75 KLK7 (0.46) MEN1KMT2AKLK7HDAC1HDAC6
SCHEMBL6215866 0.74 PDE4A (0.43) MEN1KMT2AGPR119KDM1AKDM4E
SCHEMBL9542869 0.74 ACE (0.54) KMT2AGPR119
SCHEMBL6847724 0.74 ACE (0.54) KMT2AGPR119
SCHEMBL7380297 0.74 ACE (0.54) KMT2AGPR119

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8242285-B2 N-tert-butoxycarbonyl-2-pyrrolidinones and production method thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2012-08-14 US disclosed
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2010-11-04 US disclosed
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF SUMITOMO CHEMICAL COMPANY, LIMITED (JP) 2009-06-25 US disclosed
EP-2008999-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PROCESS FOR PRODUCING THE SAME Sumitomo Chemical Company, Limited (JP) 2008-12-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090163722-A1 N-TERT-BUTOXYCARBONYL-2-PYRROLIDINONES AND PRODUCTION METHOD THEREOF TERT, CBR1, TELO2 MEN1 2455/4885KMT2A 1777/4885GPR119 3783/4885
US-20100280259-A1 N-Tert-Butoxycarbonyl-2-Pyrrolidinones and Production Method Thereof TERT, CBR1, TELO2 MEN1 2455/4885KMT2A 1777/4885GPR119 3783/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.